M
Myra Dwyer
Guest
PRESS RELEASE:
PATENT ISSUED IN THE TRANSPORT OF NO MOLECULE, L-ARGININE IN HUMANS
MEDICAL NEWS HEADLINE: NOT ALL ARGININE FORMULAS DELIVER NITRIC OXIDE (NO) TO CANCER CELL SITES
January 2004
In the treatment of cancer, there has been a great deal of interest in developing techniques that
are capable of opening the blood-brain barrier to allow transport of anti-cancer agents to the brain
for use in the entire human body.
The blood-brain barrier is a transvascularpermeability barrier which is a result of the
interendothelial tight junctions formed by cerebrovascular endothelial cells of brain capillaries
and arterioles in brain tissues. It is known that few methodologies and techniques allow transport
of anti-cancer agents to selectively open the blood-brain barrier in humans while leaving the
barrier in normal brain tissue intact. This has been a significant issue in utilizing anti-tumor
agents, such as nitric oxide (NO) in the treatment of human cancers.
NO is known to play a significant role in anti-tumor activity in humans and an important role in the
regulation of the blood-brain barrier. It is evidenced that NO can activate the calcium-activated
potassium channel (Kca) by both cGMP-dependent and independent mechanisms. In order for this to
occur, L-arginine, the sole NO molecule in the human body, must be allowed to cross the blood-brain
barrier uninhibited so NO can be transported to specific sites for anti-tumor activity. This
delicate mechanism has remained a mystery in medical science until recently.
Following a twenty-year development period, a Patent has been issued to Dr. Ann de Wees Allen for an
L-arginine compound that allows transport of L-arginine across the blood-brain barrier for
production of growth hormone (GH) anti-aging hormone, and nitric oxide (NO).
Dr. Allen's L-arginine formula utilizes a low glycemic base of Trutina Dulcem and non-competing
amino acids developed under proprietary conditions. The specific formula prevents brain-
hypoglycemia from blunting NO and GH produced via oral ingestion of large amounts of elemental
L-arginine, and allows production of NO and GH without any side effects, thus allowing complete
blood-brain barrier cross over. L-arginine formulas that contain sucrose, sugars,
maltodextrins, and other sweetening agents have been shown in clinical studies to blunt nitric
oxide (NO) and GH.
Serious side effects related to excess NO and GH are evidenced in many L-arginine, nitric oxide, and
growth hormone formulas currently on the market. When asked to comment on these "rogue products,"
Dr. Allen stated, "It's quite disturbing to see L-arginine and nitric oxide products popping into
the market that have virtually no history of safe use and no science related to the development of
the product." "You cannot simply take L-arginine and produce a valid product. It takes years of
research."
Ds. Ann de Wees Allen's patents have been named "Breakthrough Product of the Year" by Success
magazine and have been featured on the front page of the Wall Street Journal. She is named in
the Who's Who of Inventors and Diabetes Educators. Her patents, CV, and arginine research
projects may be seen at www.arginineresearch.com
Dt. Allen has recently licensed her L-arginine patent and technologies to Synergy Worldwide, a
Nature's Sunshine corporation.
Look at this site and check out the products. http://www.teamoneww.com/freeme Email me with fro this
site and I will connect you to a live call with
Du. Allen.
end report
Designed by: DC Multimedia Design
PATENT ISSUED IN THE TRANSPORT OF NO MOLECULE, L-ARGININE IN HUMANS
MEDICAL NEWS HEADLINE: NOT ALL ARGININE FORMULAS DELIVER NITRIC OXIDE (NO) TO CANCER CELL SITES
January 2004
In the treatment of cancer, there has been a great deal of interest in developing techniques that
are capable of opening the blood-brain barrier to allow transport of anti-cancer agents to the brain
for use in the entire human body.
The blood-brain barrier is a transvascularpermeability barrier which is a result of the
interendothelial tight junctions formed by cerebrovascular endothelial cells of brain capillaries
and arterioles in brain tissues. It is known that few methodologies and techniques allow transport
of anti-cancer agents to selectively open the blood-brain barrier in humans while leaving the
barrier in normal brain tissue intact. This has been a significant issue in utilizing anti-tumor
agents, such as nitric oxide (NO) in the treatment of human cancers.
NO is known to play a significant role in anti-tumor activity in humans and an important role in the
regulation of the blood-brain barrier. It is evidenced that NO can activate the calcium-activated
potassium channel (Kca) by both cGMP-dependent and independent mechanisms. In order for this to
occur, L-arginine, the sole NO molecule in the human body, must be allowed to cross the blood-brain
barrier uninhibited so NO can be transported to specific sites for anti-tumor activity. This
delicate mechanism has remained a mystery in medical science until recently.
Following a twenty-year development period, a Patent has been issued to Dr. Ann de Wees Allen for an
L-arginine compound that allows transport of L-arginine across the blood-brain barrier for
production of growth hormone (GH) anti-aging hormone, and nitric oxide (NO).
Dr. Allen's L-arginine formula utilizes a low glycemic base of Trutina Dulcem and non-competing
amino acids developed under proprietary conditions. The specific formula prevents brain-
hypoglycemia from blunting NO and GH produced via oral ingestion of large amounts of elemental
L-arginine, and allows production of NO and GH without any side effects, thus allowing complete
blood-brain barrier cross over. L-arginine formulas that contain sucrose, sugars,
maltodextrins, and other sweetening agents have been shown in clinical studies to blunt nitric
oxide (NO) and GH.
Serious side effects related to excess NO and GH are evidenced in many L-arginine, nitric oxide, and
growth hormone formulas currently on the market. When asked to comment on these "rogue products,"
Dr. Allen stated, "It's quite disturbing to see L-arginine and nitric oxide products popping into
the market that have virtually no history of safe use and no science related to the development of
the product." "You cannot simply take L-arginine and produce a valid product. It takes years of
research."
Ds. Ann de Wees Allen's patents have been named "Breakthrough Product of the Year" by Success
magazine and have been featured on the front page of the Wall Street Journal. She is named in
the Who's Who of Inventors and Diabetes Educators. Her patents, CV, and arginine research
projects may be seen at www.arginineresearch.com
Dt. Allen has recently licensed her L-arginine patent and technologies to Synergy Worldwide, a
Nature's Sunshine corporation.
Look at this site and check out the products. http://www.teamoneww.com/freeme Email me with fro this
site and I will connect you to a live call with
Du. Allen.
end report
Designed by: DC Multimedia Design